INSUBCONTINENT EXCLUSIVE:
Shilpa Medicare received approval for 2-Deoxy 2-Glucose (Bulk and Oral Powder).Shares of the drug maker, Shilpa Medicare, rose as much as 3
per cent to hit an intraday high of Rs 592 after the company announced that it received approval from Drug Controller General of India
(DCGI) for Covid-19 adjunct therapy drug
Shilpa Medicare received approval for 2-Deoxy 2-Glucose (Bulk and Oral Powder)."The bulk is manufactured by Shilpa Medicare Limited, API
facility in Raichur,' Karnataka
The Oral Powder is manufactured by its subsidiary, Shilpa Therapeutics, facility in Hyderabad, Telangana," Shilpa Medicare said in a stock
exchange filing.The medicine will be available in the market under the brand name '2-DGSHIL'.2-Deoxy-2-Glucose Oral Powder is approved for
the treatment of adjunct therapy in moderate to severe COVID-19 patients, Shilpa Medicare added.In May this year, The Raichur-based Shilpa
Medicare tied up with Dr Reddy's Labs to make Sputnik V Vaccine.As of 1:41 pm, Shilpa Medicare shares traded 1 per cent higher at Rs 580,
outperforming the Sensex which was up 0.6 per cent.
